TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10661755

Group type: EXPERIMENTAL
Intervention: Simultaneous identical bilateral movements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unilateral performance tests with the hemiplegic arm
Number of subjects: 12
Study: 8651085

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (40 mg subcutaneously per day for 25 days, n=43)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control (no treatment, n=60)
Number of subjects: 103
Study: 1521210

Group type: EXPERIMENTAL
Intervention: Low-dose prednisone (263 patients)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo (260 patients)
Number of subjects: 523
Study: 28983968

Group type: EXPERIMENTAL
Intervention: Individualized 6-mercaptopurine increments (stepwise increments of additional 25 mg/m2/day starting on days 50 and/or 71)
Number of subjects: 788

Group type: COMPARATOR
Intervention: Standard therapy (oral 6-mercaptopurine 25 mg/m2/day from days 30 to 85)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Individualized 6-mercaptopurine increments
Number of subjects: 788
Study: 26937858

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (n = 61)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Early parenteral nutrition (n = 62)
Number of subjects: 123
Study: 24958315

Group type: EXPERIMENTAL
Intervention: Continuous intra-articular infusion anesthesia
Number of subjects: 214

Group type: COMPARATOR
Intervention: Epidural infusion anesthesia
Number of subjects: 214
Study: 21105289

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LV) administered in a fixed dose schedule over 6 days
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LV)
Number of subjects: 106
Study: 18310870

Group type: EXPERIMENTAL
Intervention: AFB 84%
Number of subjects: 12

Group type: COMPARATOR
Intervention: Bicarbonate Dialysis (BD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison of AFB 84% and BD
Number of subjects: 12
Study: 15696988

Group type: EXPERIMENTAL
Intervention: Intralesional injections of 2% zinc sulfate solution
Number of subjects: 72

Group type: COMPARATOR
Intervention: Meglumine antimonate (Glucantime)
Number of subjects: 72
Study: 12789463

Group type: EXPERIMENTAL
Intervention: Californium-252 (252Cf)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Conventional gamma radiation
Number of subjects: 227
Study: 10591351

Group type: EXPERIMENTAL
Intervention: Corticosteroid (60 mg methylprednisolone IM and 12 mg dexamethasone IV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study: 9088130

Group type: EXPERIMENTAL
Intervention: Transvesical removal of the adenoma (TRA, Group 1, n = 65)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: TURP (Group 2, n = 51)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Doxazosin therapy (Group 3, n = 64)
Number of subjects: 180
Study: 1651859

Group type: EXPERIMENTAL
Intervention: Terbutaline 1.25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 20
Study: 6406700

Group type: EXPERIMENTAL
Intervention: D 25%, CAA 4.25% (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 35%, CAA 4.25% (Group 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 25%, CAA 21.3% (Group 3)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 35%, CAA 21.3% (Group 4)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 35%, CAA 2.75% (Group 5)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 25%, CAA 2.75% (Group 6)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 35%, CAA 4.25% (Group 7)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: D 25%, CAA 4.25% (Group 8)
Number of subjects: 120
Study: 31609942

Group type: EXPERIMENTAL
Intervention: Bimaxillary and chin orthognathic surgery
Number of subjects: 20
Study: 29340854

Group type: EXPERIMENTAL
Intervention: 12 sessions of fractionated thulium laser treatment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-laser treatment application of growth factor (GF) solution
Number of subjects: 10
Study: 26926656

Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy
Number of subjects: 416

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Positive airway pressure therapy (adherent group)
Number of subjects: 416
Study: 25209521

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 1% cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozenoxacin 2% cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26845802

Group type: EXPERIMENTAL
Intervention: Foam dressing in NPWT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gauze dressing in NPWT
Number of subjects: 0
Study: 20301819

Group type: EXPERIMENTAL
Intervention: Catheter perpendicular to the nerve
Number of subjects: 50

Group type: COMPARATOR
Intervention: Catheter parallel to the nerve
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 16231362

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 41
Study: 12678340

Group type: EXPERIMENTAL
Intervention: NaP (oral sodium phosphate)
Number of subjects: 72

Group type: COMPARATOR
Intervention: PEG (polyethylene glycol electrolyte lavage solution)
Number of subjects: 72
Study: 10740542

Group type: EXPERIMENTAL
Intervention: Dopexamine 1.0 mg kg‐1 over 5 min, followed by an infusion of 2 micrograms kg‐1 min‐1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (equal volume to dopexamine)
Number of subjects: 50
Study: 8598592

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 1430505

Group type: EXPERIMENTAL
Intervention: Dentifrices containing fluoride at levels of 1250, 2500, and 5000 ppm
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Dentifrices containing 15 mg percent xylitol
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 520
Study: 3972929

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (6 standardized sessions, one hourly session per week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hypnotherapy
Number of subjects: 48
Study: 31855909

Group type: EXPERIMENTAL
Intervention: 12-week single-legged decline-squat exercise
Number of subjects: 34

Group type: COMPARATOR
Intervention: 12-week single-legged decline-squat exercise + weekly session of ESWT for 6 weeks
Number of subjects: 34
Study: 29940797

Group type: EXPERIMENTAL
Intervention: Tele-delivered mindfulness-based cognitive therapy
Number of subjects: 8
Study: 27206513

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 54
Study: 26958009

Group type: EXPERIMENTAL
Intervention: Early amniotomy
Number of subjects: 214

Group type: COMPARATOR
Intervention: Conservation of membranes (Control)
Number of subjects: 214
Study: 23877988

Group type: EXPERIMENTAL
Intervention: Sitagliptin alone or in combination with glargine insulin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Basal bolus insulin regimen (glargine and lispro) plus supplemental doses of lispro
Number of subjects: 90
Study: 21283736

Group type: EXPERIMENTAL
Intervention: Virtual Hospital (Arm I)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard Care (Arm II)
Number of subjects: 83
Study: 20108652

Group type: EXPERIMENTAL
Intervention: Test formulation (Bellissima)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation
Number of subjects: 20
Study: 16426094

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Lithium (serum concentration 0.6 to 1.2 mEq/L)
Number of subjects: 431
Study: 15450048

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (OS) for 3 months
Number of subjects: 91

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 91
Study: 11575169

Group type: EXPERIMENTAL
Intervention: Classroom mind/body wellness intervention
Number of subjects: 243

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 243
Study: 9600501

Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 8010268

Group type: EXPERIMENTAL
Intervention: SHARE fast spin-echo imaging technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional long-repetition-time spin-echo imaging
Number of subjects: 50
Study: 2511590

Group type: EXPERIMENTAL
Intervention: 12-session smoking prevention program
Number of subjects: 608
Study: 1094565

Group type: EXPERIMENTAL
Intervention: Pyrithioxine (Encephabol)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 44
Study: 31853103

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.5mg/kg in 5ml
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (5ml 0.9% saline)
Number of subjects: 64
Study: 28013123

Group type: EXPERIMENTAL
Intervention: Intranasal insulin 40 IU taken four times a day (QID)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 26174460

Group type: EXPERIMENTAL
Intervention: Avena sativa lotion, twice a day for 2 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Diluted vinegar, for 2 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hydroxyzine tablets, for 2 weeks
Number of subjects: 23
Study: 23233371

Group type: EXPERIMENTAL
Intervention: ExPeak‐Reg
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: ExRec‐Reg
Number of subjects: 531

Group type: COMPARATOR
Intervention: Rest‐Reg
Number of subjects: 531
Study: 21626403

Group type: EXPERIMENTAL
Intervention: Mid-septum lead placement
Number of subjects: 286

Group type: COMPARATOR
Intervention: Right ventricular apex lead placement
Number of subjects: 286
Study: 18562464

Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - School-based programme (16 sessions in 3 years)
Number of subjects: 1952

Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention
Number of subjects: 1952
Study: 16866675

Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 75

Group type: COMPARATOR
Intervention: Condom catheter
Number of subjects: 75
Study: 12964648

Group type: EXPERIMENTAL
Intervention: Experimental group received antimicrobial treatment (topical application of NaF and iodine solution) and restorative care using glass ionomer cement.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group received primary care intervention and oral hygiene kits.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Both groups received primary care intervention and oral hygiene kits.
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Maternal caries increase was a significant factor influencing the caries experience of the children.
Number of subjects: 81
Study: 11518470

Group type: EXPERIMENTAL
Intervention: Fibrin-glue coated collagen patch
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard closure
Number of subjects: 60
Study: 9401830

Group type: EXPERIMENTAL
Intervention: Carbamazepine 400 mg retard AWD (test)
Number of subjects: 18
Study: 8269790

Group type: COMPARATOR
Intervention: Usual Care group intervention
Number of subjects: 6000
Study: 2851386

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (B) 0.3 gm/kg body weight
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (B)
Number of subjects: 65
Study: 30082118

Group type: EXPERIMENTAL
Intervention: Early revascularization (in patients with pulse pressure < 60 mmHg)
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (in patients with pulse pressure < 60 mmHg)
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Early revascularization (in patients with pulse pressure ≥ 60 mmHg)
Number of subjects: 2294

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (in patients with pulse pressure ≥ 60 mmHg)
Number of subjects: 2294

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2294
Study: 27813395

Group type: EXPERIMENTAL
Intervention: Precise liver resection using simplified blocking combined with electrotome (Group A)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Precise liver resection using half‐hepatic occlusion + CUSA assisting liver parenchyma transection + lower central venous pressure (Group B)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 61

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 61
Study: 24547757

Group type: EXPERIMENTAL
Intervention: Mastery-oriented assessment
Number of subjects: 192

Group type: COMPARATOR
Intervention: Performance-oriented assessment
Number of subjects: 192

Group type: COMPARATOR
Intervention: No assessment
Number of subjects: 192
Study: 22734586

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) at a fixed dose of 10 mg/kg/day for 18 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20371785

Group type: EXPERIMENTAL
Intervention: Methotrexate therapy for 6 months (group 1, n = 183)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Methotrexate therapy for 12 months (group 2, n = 181)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Methotrexate therapy for 6 months (group 1)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Methotrexate therapy for 12 months (group 2)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: MRP8/14 levels during remission
Number of subjects: 364
Study: 17325227

Group type: EXPERIMENTAL
Intervention: Fosmidomycin‐clindamycin therapy given every 12 h for 3 days
Number of subjects: 105

Group type: COMPARATOR
Intervention: Sulfadoxine‐pyrimethamine (single oral dose)
Number of subjects: 105
Study: 15685261

Group type: EXPERIMENTAL
Intervention: Annual comprehensive preventative health evaluation (CPHE)
Number of subjects: 853
Study: 12149659

Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects (not treated with efonidipine)
Number of subjects: 0
Study: 9539595

Group type: EXPERIMENTAL
Intervention: Selective group (R and MC nerves blocked with 10 mL of 2% lidocaine each; M and U nerves blocked with 10 mL of 0.5% bupivacaine each)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (each of the four nerves infiltrated with 10 mL of a mixture of 2% lidocaine and 0.5% bupivacaine)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 7530868

Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 0

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 0
Study: 2792786

Group type: EXPERIMENTAL
Intervention: Physical exercise training (PET)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonexercise control (NEC)
Number of subjects: 14
Study: 378626

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bid
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30945504

Group type: EXPERIMENTAL
Intervention: Internal heat-type acupuncture needle therapy (IHTAN), 42 ℃, 20 min, once a week for 4 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Warm needle moxibustion therapy, once every other day for 4 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IHTAN
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 28917230

Group type: EXPERIMENTAL
Intervention: 400 mg green coffee bean extract for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 25817296

Group type: EXPERIMENTAL
Intervention: Rituximab (R) plus cyclophosphamide, vincristine and prednisone
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: R plus cyclophosphamide, doxorubicin, vincristine and prednisone
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: R plus mitoxantrone and fludarabine
Number of subjects: 428
Study: 23924205

Group type: EXPERIMENTAL
Intervention: Short transverse (ST) incision
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hockey-stick (HS) incision
Number of subjects: 66
Study: 20825915

Group type: EXPERIMENTAL
Intervention: Pentax AWS videolaryngoscope (PAV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MAC)
Number of subjects: 0
Study: 20003351

Group type: EXPERIMENTAL
Intervention: Co-bedding group
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 128
Study: 17046017

Group type: EXPERIMENTAL
Intervention: Working memory involvement in arithmetic strategy selection and efficiency
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual differences (processing speed, arithmetic skill, gender, math anxiety)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term memory capacity
Number of subjects: 0
Study: 16391244

Group type: EXPERIMENTAL
Intervention: Short arm cast
Number of subjects: 113

Group type: COMPARATOR
Intervention: Long arm cast
Number of subjects: 113
Study: 14661011

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Streptokinase (SK)
Number of subjects: 112
Study: 10348277

Group type: EXPERIMENTAL
Intervention: Psychoeducational group program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control intervention (written information and brief counseling)
Number of subjects: 32
Study: 8747271

Group type: EXPERIMENTAL
Intervention: Pedicle screw fixation
Number of subjects: 0
Study: 1673495

Group type: EXPERIMENTAL
Intervention: ICI 204,219 (40 mg by mouth)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7047329

Group type: EXPERIMENTAL
Intervention: Intravenous and intrathecal immunoglobulin (Ig) therapy: 10 g Ig as a short infusion on two consecutive days, plus 500 mg by intrathecal injection every second day for bacterial infections and every fifth day for viral infections.
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group received usual therapy only, principally antibiotics for purulent meningitis.
Number of subjects: 68
Study: 31631409

Group type: EXPERIMENTAL
Intervention: FatSegNet (automated deep learning pipeline)
Number of subjects: 0
Study: 31237459

Group type: EXPERIMENTAL
Intervention: Values and Options in Cancer Care intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 28514807

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2 mA, 20 min)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study: 24622414

Group type: EXPERIMENTAL
Intervention: Alefacept (15 mg intramuscularly per week for two 12-week courses, separated by a 12-week pause)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 49
Study: 21703824

Group type: EXPERIMENTAL
Intervention: HI-NEG patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: LOW-NEG patients
Number of subjects: 59

Group type: COMPARATOR
Intervention: CN patients
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Higher self-reported trait negative affect
Number of subjects: 59
Study: 18813407

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg (group K)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pethidine 0.5 mg/kg (group P)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (group S)
Number of subjects: 120
Study: 17217869

Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ergotamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0
Study: 12781852

Group type: EXPERIMENTAL
Intervention: 400 microg/d folic acid supplement
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 10692621

Group type: EXPERIMENTAL
Intervention: Systemic lidocaine (2 mg/kg bolus followed by 2 mg kg(‐1)h(‐1) infusion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Regional lidocaine (40 ml lidocaine, 0.05%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (40 ml NaCl, 0.9%)
Number of subjects: 12
Study: 9459116

Group type: EXPERIMENTAL
Intervention: Intravenous polyvalent immunoglobulins (IVIG) at a dose of 1 g/kg for 3 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (ICU patients not receiving IVIG)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Non-ICU, noninfected patients
Number of subjects: 41
Study: 1585493

Group type: EXPERIMENTAL
Intervention: Euro-Collins (EC) in situ flush
Number of subjects: 56

Group type: COMPARATOR
Intervention: University of Wisconsin (UW) in situ flush
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both EC and UW solutions
Number of subjects: 56
Study: 3001233

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 17
Study: 29618436

Group type: EXPERIMENTAL
Intervention: Survanta
Number of subjects: 150

Group type: COMPARATOR
Intervention: Curosurf
Number of subjects: 150
Study: 26509765

Group type: EXPERIMENTAL
Intervention: i‐gel (laryngeal mask)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 110
Study: 24622832

Group type: EXPERIMENTAL
Intervention: Tryptophan (2 x 500 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Melatonin (2 x 5 mg/day) and Essentiale forte (3 x 1 tablet/day) for 14 months
Number of subjects: 74

Group type: COMPARATOR
Intervention: Essentiale forte only for 14 months
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Tryptophan and melatonin (groups I and II)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Essentiale forte only (group III)
Number of subjects: 74
Study: 24245493

Group type: COMPARATOR
Intervention: Online after-care program, conducted once per week for eight weeks.
Number of subjects: 0
Study: 20435245

Group type: EXPERIMENTAL
Intervention: Test formulation of tramadol 100 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference formulation of tramadol 100 mg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 26